Author(s):
Pratibha Tiwari, Pratixa Patel
Email(s):
E-mail:
DOI:
10.52711/2231-5713.2024.00060 
Address:
Pratibha Tiwari1*, Pratixa Patel2
1ROFEL Shri G.M. Bilakhia College of Pharmacy, Vapi, Gujarat, 396191, India.
2Department of Pharmacology, ROFEL Shri G.M. Bilakhia College of Pharmacy, Vapi, Gujarat, 396191, India.
*Corresponding Author
Published In:
Volume - 14,
Issue - 4,
Year - 2024
ABSTRACT:
This review examines the World Health Organization's efforts to eradicate poliovirus (PV) through the use of Inactivated Polio Vaccine (IPV) and Oral Polio Vaccine (OPV). While OPV is effective in preventing disease and limiting transmission, it carries risks such as rare paralysis and the emergence of vaccine-derived strains. With Type 1 wild-type PV still a threat despite the eradication of Types 2 and 3, a strategic shift towards global IPV adoption is critical to eliminate these risks. The review highlights the challenges of vaccine development for immunocompromised individuals and explores the differing mechanisms, benefits, and drawbacks of IPV and OPV. It also addresses the complexities of vaccine manufacturing, emphasizing the need for ongoing research to support global eradication efforts. A comprehensive understanding of vaccination strategies is essential as the world moves towards a polio-free future.
Cite this article:
Pratibha Tiwari, Pratixa Patel. Critical Insights into Polio Vaccination: Balancing Risks, Benefits and Future Directions. Asian Journal of Pharmacy and Technology. 2024; 14(4):379-5. doi: 10.52711/2231-5713.2024.00060
Cite(Electronic):
Pratibha Tiwari, Pratixa Patel. Critical Insights into Polio Vaccination: Balancing Risks, Benefits and Future Directions. Asian Journal of Pharmacy and Technology. 2024; 14(4):379-5. doi: 10.52711/2231-5713.2024.00060 Available on: https://ajptonline.com/AbstractView.aspx?PID=2024-14-4-13
REFERENCES:
1. Bazin H. Introduction. In The Eradication of Smallpox; Bazin, H., Ed.; Academic Press: London, UK, 2000; pp. XIX–XX.
2. Bandyopadhyay A.S.; Zipursky S. A Novel Tool to Eradicate an Ancient Scourge: The Novel Oral Polio Vaccine Type 2 Story. Lancet Infect. Dis. 2023; 23: e67–e71.
3. Sharma N.C.; Efstratiou A.; Mokrousov I.; Mutreja A.; Das B.; Ramamurthy T. Diphtheria. Nat. Rev. Dis. Prim. 2019; 5: 81.
4. Rehan Haider. Vaccine through Centuries. Major Cornerstone of Global Health. Asian Journal of Pharmacy and Technology. 2023; 13(1): 65-9. doi: 10.52711/2231-5713.2023.00013
5. Brisse M.; Vrba S.M.; Kirk N.; Liang Y.; Ly H. Emerging Concepts and Technologies in Vaccine Development. Front. Immunol. 2020.
6. Zaffran, M. Vaccine Transport and Storage: Environmental Challenges. Dev. Biol. Stand. 1996; 87: 9–17.
7. Bandyopadhyay AS, Garon J, Seib K, Orenstein WA. Polio Vaccination: Past, Present, and Future. Future Microbial. 2015; 10(5): 791-808.
8. Lei H.; Sheng Z.; Ding Q.; Chen J.; Wei X.; Lam D.M.-K.; Xu Y. Evaluation of Oral Immunization with Recombinant Avian Influenza Virus HA1 Displayed on the Lactococcus lactis Surface and Combined with the Mucosal Adjuvant Cholera Toxin Subunit B. Clin. Vaccine Immunol. 2011; 18: 1046–1051.
9. Lei H.; Gao T.; Hamicd Y.; Howard J.; Liu J.; Davidson R.; Tong R.; Lam O.Y.; Lam F.W.; Lam D.M.-K. The Development of a Yeast-derived Oral Vaccine against Hepatitis B. Biotechnol. Hong Kong 2020; 4: 123–134.
10. Ponnambily Chandy, Grace Rebekah J, Angeline Jeya Rani K., Esther Kanthi. K, Prasanna Kumari Sathianathan., K. Imnainla Walling, Anmery Varghese Pulikkottil. Global COVID 19 distribution and its association with the selected demographic variables of the countries: A Cross-sectional Infodemiological approach at 10th month of Pandemic. International Journal of Nursing Education and Research. 2022; 10(2): 99-3. doi: 10.52711/ 2454-2660.2022.00023
11. Kunisawa J.; Kurashima Y.; Kiyono H. Gut-associated Lymphoid Tissues for the Development of Oral Vaccines. Adv. Drug Deliv. Rev. 2012; 64: 523–530.
12. Kwong K.W.-Y.; Xin Y.; Lai N.C.-Y.; Sung J.C.-C.; Wu K.-C.; Hamied Y.K.; Sze E.T.-P.; Lam, D.M.-K. Oral Vaccines: A Better Future of Immunization. Vaccines 2023; 11: 1232.
13. Zhang Y.; Li M.; Du G.; Chen X.; Sun X. Advanced Oral Vaccine Delivery Strategies for Improving Immunity. Adv. Drug Deliv. Rev. 2021; 177: 113928.
14. Sanofi Pasteur. Oral Bivalent Types 1 and 3 Poliomyelitis Vaccine Package Insert.
15. Hawken J, Troy SB. Adjuvants and Inactivated Polio Vaccine: A Systematic Review. Vaccine. 2012 Nov 19; 30(49): 6971-9.
16. WHO. Working Draft GAPIII: WHO Global Action Plan to Minimize Poliovirus Facility-associated Risk after Type-specific Eradication of Wild Polioviruses and Sequential Cessation of Routine OPV Use.
17. Pollard AJ, Bijker EM. A Guide to Vaccinology: From Basic Principles to New Developments. Nat Rev Immunol. 2021 Feb; 21.
18. World Health Statistics 2023: Monitoring Health for the SDGs, Sustainable Development Goals. Geneva: World Health Organization; 2023. Licence: CC BY NC SA 3.0 IGO. Pg:44.
19. Thomassen YE, Rubingh O, Wijffels RH, van der Pol LA, Bakker WA. Improved Poliovirus D-antigen Yields by Application of Different Vero Cell Cultivation Methods. Vaccine. 2014; 32(24): 2782-2788.
20. Rolli G. Progress toward a Low cGMP Per.c6-based IPV. WHO.
21. Poliomyelitis (website). Geneva: World Health Organization; 2022.
22. Global Polio Eradication Initiative (website). Geneva: World Health Organization.
23. Polio Eradication Strategy 2022–2026. Delivering on a Promise. Geneva: World Health Organization on Behalf of the Global Polio Eradication Initiative; 2021.
24. https://www.unicef.org/
25. Thomassen YE, Van ‘t Oever AG, Van Oijen MG, et al. Next Generation Inactivated Polio Vaccine Manufacturing to Support Post-Polio-Eradication Biosafety Goals. PLoS One. 2013; 8(12): e83374.
26. Yeh MT, Bujaki E, Dolan PT, Smith M, Wahid R, Konz J, Weiner AJ, Bandyopadhyay AS, Van Damme P, De Coster I, Revets H, Macadam A, Andino R. Engineering the Live-attenuated Polio Vaccine to Prevent Reversion to Virulence. Cell Host Microbe. 2020 May 13; 27(5): 736-751.
27. Wyman O. The Supply Landscape and Economics of IPV-containing Combination Vaccines: Key Findings.
28. Kalkowska DA, Pallansch MA, Wilkinson A, Bandyopadhyay AS, Konopka-Anstadt JL, Burns CC, Oberste MS, Wassilak SGF, Badizadegan K, Thompson KM. Updated Characterization of Outbreak Response Strategies for 2019-2029: Impacts of Using a Novel Type 2 Oral Poliovirus Vaccine Strain. Risk Anal. 2021; 41(2): 329-348.
29. Lorenzetti L, Heydarov R, Namey E, Lawton A, Nam H, Ridwan Hasan M, Monj C, Obeysekera S, Amina Kabwau M, McIntosh R. Exploring Public Perceptions of Vaccine-derived Poliovirus and a Novel Oral Polio Vaccine in the Democratic Republic of the Congo, Kenya, and Nigeria. Vaccine. 2023 Apr 6; 41 Suppl 1: A128-A135.
30. Yeh MT, Smith M, Carlyle S, Konopka-Anstadt JL, Burns CC, Konz J, Andino R, Macadam A. Genetic Stabilization of Attenuated Oral Vaccines against Poliovirus Types 1 and 3. Nature. 2023 Jul; 619(7968): 135-142.
31. Voorman A, Lyons H, Bennette C, Kovacs S, Makam JK, F Vertefeuille J, Tallis G. Analysis of Population Immunity to Poliovirus Following Cessation of Trivalent Oral Polio Vaccine. Vaccine. 2023 Apr 6; 41 Suppl 1: A85-A92.
32. Itoh E, Shimizu S, Ami Y, Iwase Y, Someya Y. Dose-sparing Effect of Sabin-derived Inactivated Polio Vaccine Produced in Japan by Intradermal Injection Device for Rats. Biologicals. 2023 May; 82: 101677.
33. A. Ch. Sravanthi, K. Venkata Lakshmi, K.T.N. Jyothi. Mathematical modeling in Epidemiology. Research J. Science and Tech. 2017; 9(3): 353-354. doi: 10.5958/2349-2988.2017.00061.4
34. Niloy Sarkar, Bijoy Kumar Mandal, Soumya Paul. Activity, Effect on Human and Salvation from effect of COVID-19. Asian Journal of Management. 2021; 12(2): 228-4. doi: 10.52711/2321-5763.2021.00035
35. Sarfaraz Ahmad, Ambreen Shoaib, Md. Sajid Ali, Md. Sarfaraz Alam, Nawazish Alam, Maksood Ali, Md. Ali Mujtaba, Ayaz Ahmad, Md. Salahuddin Ansari, Mohammad Daud Ali. Epidemiology, Risk, Myths, Pharmacotherapeutic Management and Socio- economic Burden due to Novel COVID-19: A Recent Update. Research Journal of Pharmacy and Technology. 2021; 14(4):2308-5. doi: 10.52711/0974-360X.2021.00408
36. Subhadeep Mukherjee. Bhagavad Gita: The Key Source of Modern Management. Asian J. Management; 2017; 8(1): 68-72. doi: 10.5958/2321-5763.2017.00010.5
37. Surekha, Anoop Kumar, Harit Kasana, Jaipal Meena, Archana Sayal. Comparative Evaluation of HEP-2(Cincinnati) and Vero cell lines sensitivity to Bivalent Oral Polio Virus Vaccine (Type 1 and Type 3) by using In-vitro Microtitration Potency Assay. Research Journal of Pharmacy and Technology 2023; 16(10): 4719-2. doi: 10.52711/0974-360X.2023.00766
38. Dibya Jyoti Saha, Mayukh Jana, Supradip Mandal. Target Discovery and Validation: Advances in Molecular Pharmacology. Asian J. Pharm. Ana. 2011; 1(2): 27-28.
39. Vignesh Balaji E, Tamil Selvan A. Nano pharmacology: A Novel Approach in Therapeutics. Asian J. Res. Pharm. Sci. 2019; 9(1): 09-16. doi: 10.5958/2231
40. Santosh Kumar Gautam. Mass Media and Pulse Polio Awareness Campaign. Int. J. Rev. and Res. Social Sci. Jan.- Mar., 2017; 5(1): 15- 21. doi: 10.5958/2454-2687.2017.00002.8